Buprenorphine in the treatment of non-suicidal self-injury: A case series and discussion of the literature

International Journal of Adolescent Medicine and Health

Volumn 25, Issue 3, 2013, Pages 323-330

  Norelli, Lisa J ^a,b,c   Smith, Howard S ^b   Sher, Leo ^d,e   Blackwood, Tracey A ^a  

^a Capital District Psychiatric Center   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Developmental disorders; Nonsuicidal self injury; Opioid system; Psychiatric disorders

Indexed keywords

ANTIDEPRESSANT AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALTREXONE; CLOZAPINE; UNCLASSIFIED DRUG; MU OPIATE RECEPTOR; NARCOTIC ANTAGONIST;

ADULT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BORDERLINE STATE; BRAIN ATROPHY; BRAIN CORTEX; BULIMIA; CLINICAL ARTICLE; CONDUCT DISORDER; DISSOCIATIVE DISORDER; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; ESOPHAGUS PERFORATION; FATIGUE; FEMALE; FOREIGN BODY; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR DEPRESSION; MALE; NAUSEA; NON SUICIDAL SELF INJURY; POSTTRAUMATIC STRESS DISORDER; SCHIZOAFFECTIVE PSYCHOSIS; SEXUAL DEVIATION; SUBSTANCE ABUSE; YOUNG ADULT; CASE REPORT; CHILD ABUSE; DISABLED PERSON; DRUG POTENTIATION; HOSPITALIZATION; PSYCHOLOGICAL AND PSYCHIATRIC PROCEDURES; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; TREATMENT OUTCOME; AGONISTS; PSYCHOLOGY; SECONDARY PREVENTION; SELF-INJURIOUS BEHAVIOR;

ADULT; ADULT SURVIVORS OF CHILD ABUSE; BUPRENORPHINE; DISABLED PERSONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; NARCOTIC ANTAGONISTS; PSYCHOLOGICAL TECHNIQUES; RECEPTORS, OPIOID, MU; RECURRENCE; SELF-INJURIOUS BEHAVIOR; TREATMENT OUTCOME; SECONDARY PREVENTION;

EID: 84892386856     PISSN: 03340139     EISSN: 21910278     Source Type: Journal    
DOI: 10.1515/ijamh-2013-0069     Document Type: Article

References (47)

1. Jacobson CM, Gould M. The epidemiology and phenomenology of non-suicidal self-injurious behavior among adolescents: a critical review of the literature. Arch Suicide Res 2007;11:129-47.
2. Sinclair J, Gray A, Rivero-Arias O, Saunders K, Hawton K. Healthcare and social services resource use and costs of self-harm patients. Soc Psychiatr Psychiatric Epidemiol 2011;46:263-71.
3. Whitlock J, Knox KL. The relationship between self-injurious behavior and suicide in a young adult population. Arch Pediatr Adolesc Med 2007;161:634-40.
4. Glenn CR, Klonsky ED. Prospective prediction of nonsuicidal self-injury: a 1-year longitudinal study in young adults. Behav Ther 2011;42:751-62.
5. Hawton K, Fagg J. Suicide, and other causes of death, following attempted suicide. Br J Psychiatry 1988;152:359-66.
6. Herpertz S. Self-injurious behaviour. Psychopathological and nosological characteristics in subtypes of self-injurers. Acta Psychiatr Scand 1995;91:57-68.
7. Zlotnick C, Mattia JI, Zimmerman M. Clinical correlates of self-mutilation in a sample of general psychiatric patients. J Nerv Ment Dis 1999;187:296-301.
8. Briere J, Gil E. Self-mutilation in clinical and general population samples: prevalence, correlates, and functions. Am J Orthopsychiatry 1998;68:609-20.
9. Klonsky ED, Oltmanns TF, Turkheimer E. Deliberate self-harm in a nonclinical population: prevalence and psychological correlates. Am J Psychiatry 2003;160:1501-8.
10. Norelli LJ, Coates AD, Kovasznay BK. Cancer risk from diagnostic radiology in a deliberate self-harm patient. Acta Psychiatr Scand 2010;122:427-30.
11. Selby EA, Bender TW, Gordon KH, Nock MK, Joiner TE Jr. Non-suicidal self-injury (NSSI) disorder: a preliminary study. Personal Disord 2012;3:167-75.
12. Nonsuicidal self-injury. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Publishing, 2013: 783-808.
13. Moscicki EK, O Carroll P, Rae DS, Locke BZ, Roy A, et al. Suicide attempts in the Epidemiologic Catchment Area Study. Yale J Biol Med 1988;61:259-68.
14. Schmidtke A, Bille-Brahe U, De Leo D, Kerkhof A, Bjerke T, et al. Attempted suicide Europe: rates, trends, and sociodemographic characteristics of suicide attempters during the period 1989-1992. Results of the WHO/EURO Multicentre Study on Parasuicide. Acta Psychiatr Scand 1996;93:327-38.
15. Nock MK, Joiner TE, Gordon KH, Lloyd-Richardson E, Prinstein MJ. Non-suicidal self-injury among adolescents: diagnostic correlates and relation to suicide attempts. Psychol Res 2006;144:65-72.
16. Sher L, Stanley BH. The role of endogenous opioids in the pathophysiology of self-injurious and suicidal behavior. Arch Suicide Res 2008;12:299-308.
17. Prossin AR, Love TM, Koeppe RA, Zubeita J, Silk KR. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry 2010;167:925-33.
18. Kennedy SE, Koeppe RA, Young EA, Zubeita J. Dysregulation of opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006;63:1199-208.
19. Mercer D. Medications in the treatment of borderline personality disorder 2006. Curr Psychiatry Rep 2007;9:53-62.
20. Bystritsky A, Strausser BP. Treatment of obsessivecompulsive cutting behavior with naltrexone. J Clin Psychiatry 1996;57:423-4.
21. McGee MD. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. J Clin Psychiatry 1997;58:32-3.
22. Agarwal LJ, Berger CE, Gill L. Naltrexone for severe self-harm behavior: a case report. Am J Psychiatry 2011;168:437-8.
23. Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry 1996;57:233-7.
24. Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011;57:281-9.
25. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 2002;161:1-16.
26. Ide S, Minami M, Satoh M, Uhl GR, Sora I, et al. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in ?-opioid receptor knockout mice. Neuropsychopharmacology 2004;29:1656-63.
27. Robinson SE. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 2002;8:377-90.
28. Wnendt S, Krüger T, Janocha E, Hildebrandt D, Englberger W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptortriggered gene assay. Mol Pharmacol 1999;56:334-8.
29. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 2000;21:1141-6.
30. Leander DJ. Opioid agonist and antagonist behavioral effects of buprenorphine. Br J Pharmacol 1983;78:607-15.
31. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid-dependent humans. J Pharmacol Exp Ther 1988;247:47-53.
32. Walker EA, Zernig G, Woods JH. Buprenorphine antagonism of opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 1995;273:1345-52.
33. Woods JH, France CP, Winger GD. Behavioral pharmacology of buprenorphine: issues relevant to its potential in treating abuse. NIDA Res Monogr 1992;121:12-27.
34. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537-45.
35. Dum JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981;74:627-33.
36. Villiger J, Taylor K. Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 1981;29: 2699-2708.
37. Boas R, Villiger J. Clinical actions of fentanyl and buprenorphine. Br J Anaesth 1985;57:192-6.
38. Rance MJ, Dickens JM. The influence of drug-receptor kinetics on the pharmacological and pharmacokinetic profiles of buprenorphine. In: Van Ree J, Terenius L, editors. Characteristics and functions of opioids. Amsterdam: Elsevier, 1978:65-6.
39. Mello NK, Bree MP, Mendelson JH. Buprenorphine self administration by rhesus monkeys. Pharmacol Biochem Behav 1981;15:215-25.
40. Dykstra LA. Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys. J Pharmacol Exp Ther 1983;226:317-23.
41. France CP, Jacobson AE, Woods JH. Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. J Pharmacol Exp Ther 1984;230:652-7.
42. France CP, Woods JH. Opiate agonist-Antagonist interactions: application of a three-key drug discrimination procedure. J Pharmacol Exp Ther 1985;234:81-9.
43. Young AM, Kapitsopoulos G, Makhay MM. Tolerance to morphine-like stimulus effects of opioid agonists. J Pharmacol Exp Ther 1991;257:795-805.
44. Brandt MR, Cabansag SR, France CP. Discriminative stimulus effects of 1-?-Acetylmethadol (LAAM), buprenorphine and methadone in morphine-Treated rhesus monkeys. J Pharmacol Exp Ther 1997;282:574-84.
45. Briscoe RJ, Winger G, Lewis JW, Woods JH. Methoclocinnamox: time course of changes in alfentanil reinforced responding in rhesus monkeys. Psychopharmacology 2000;148:393-9.
46. Mogil JS, Wilson SG, Chesler EJ, Rankin AL, Nemmani KV, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 2003;100:4867-72.
47. Steiner H, Gerfen CR. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 1998;123:60-76.